Home Tags HER2

Tag: HER2

Targeting Breast Cancer with more Punch

To optimize current treatment and develop methods to more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells...

Ado-trastuzumab Emtansine Fails Phase II/III GATSBY trial

Earlier today, in a short statement to the U.S. Securities Exchange Commission (SEC), ImmunoGen, Inc. disclosed that the Phase II/III Gatsby trial, a clinical...

Antibody-drug Conjugate Potential for Metastatic Breast Cancer Treatment Shown Through Results...

In 2012, an estimated 2,975,314 women were living with breast cancer, representing about 12% of all new cancer cases and 25% of all cancers...

MI130004, a New ADC Using a Marine Compound, Shows Promising Therapeutic...

Over the last decade, antibody–drug conjugates or ADCs have emerged as powerful tool for the treatment of patients with cancer and hematological disorders.  These...

HER2+ Metastatic Breast Cancer and CNS metastases: A Retrospective, Exploratory Analysis...

The development of targeted antibody-drug conjugates (ADC) for the treatment of cancer represents a significant - and promising - progress. ADCs are precise and...

Second Generation HER2-antibody-drug conjugate Offers Best-in-Class Potential and Improved Therapeutic Index

In pre-clinical xenograft studies using patient-derived breast cancer and non-small-cell lung cancer material, Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported...

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...

FEATURED RESOURCES